Related Experiment Videos
Respiratory disorders in common variable immunodeficiency
M A Martínez García1, M D de Rojas, M D Nauffal Manzur
1Department of Pneumology, Hospital Universitario La Fe, Valencia, Spain. med013413@nacom.es
Respiratory Medicine
|March 27, 2001
Summary
Common variable immunodeficiency (CVID) frequently causes lung problems. Intravenous immunoglobulin replacement therapy significantly reduced pneumonia episodes in CVID patients, improving respiratory health.
Area of Science:
- Immunology
- Pulmonology
- Internal Medicine
Background:
- Common variable immunodeficiency (CVID) is a primary immunodeficiency syndrome.
- CVID is characterized by hypogammaglobulinemia, increased susceptibility to infections, and immune dysregulation.
- Pulmonary complications are a major cause of morbidity and mortality in CVID patients.
Purpose of the Study:
- To determine the prevalence of lung involvement in CVID patients.
- To evaluate the efficacy of intravenous immunoglobulin replacement therapy (IVIgRT) in managing pulmonary complications in CVID.
Main Methods:
- Retrospective analysis of 19 CVID patients treated with IVIgRT.
- Pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT) were performed.
- Infection rates before and after IVIgRT were compared.
Main Results:
- Bronchiectasis was diagnosed in 58% of patients, with 42% having multi-lobar involvement.
- Chronic airflow limitation (CAL) was present in 53% of patients.
- Pneumonia episodes decreased significantly after IVIgRT (0.28 to 0.16 per patient-year).
Conclusions:
- Lung involvement, including bronchiectasis and CAL, is highly prevalent in CVID.
- Long-term IVIgRT is effective in reducing the frequency of pneumonia in CVID patients.
- IVIgRT plays a crucial role in managing pulmonary complications and improving outcomes in CVID.